Company intelligence / Profile preview

Vivoryon Therapeutics N.V.

Halle, Sachsen-Anhalt, Germanyvivoryon.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Varoglutamstat has completed Phase 2b clinical trials (VIVIAD) for Alzheimer's disease with results reported in Q1 2024. The company is also conducting VIVA-MIND Phase 2 study in the US. Recent data showed unique treatment effects of varoglutamstat on kidney function in patients with diabetes, leading to plans for a Phase 2 study in diabetic kidney disease (DKD)[5][7][9].

Therapeutic areas: OncologyNeurologyNephrology
Modalities: Small molecule-based medicines
Industry: Biotech

Drug pipeline

7 assets

varoglutamstat

6 more assets in the full pipeline.

Request access →

Partnerships

Nordic Bioscience for clinical development of PQ912 for Alzheimer's diseaseFraunhofer Institute for cell therapy and immunologySimcere Pharmaceutical Group Ltd. for development and commercialization in Alzheimer's disease[2]

Beyond the preview

Go deeper on Vivoryon Therapeutics N.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivoryon Therapeutics N.V..

Explore the full profile